Genentech Fitting Better

Genentech (NYSE: DNA  ) released its third-quarter financial results yesterday. Like an overweight businessman losing pounds and fitting into his suit better, Genentech's previous lofty P/E valuation continues to come down as it boosts its bottom line every quarter, yet has a slightly lower share price for the year.  

Genentech continued its streak of double-digit growth in its top and bottom lines in the quarter, with a year-over-year 22% gain in revenue and 22% gain in net income after excluding one-time charges. Importantly, Genentech is managing to keep its non-R&D expenditures in check as its bottom line grew at the same speed as its top line, even though research and development spending was up 38% in the quarter.

Its top drug, cancer treatment Avastin, is still experiencing torrid expansion, as sales of the drug were up 37% year over year, making up for the mediocre 6% growth in Herceptin as it comes under competitive attack from GlaxoSmithKline's (NYSE: GSK  ) Tykerb.

Dozens of clinical trials have expanded Avastin's uses to include every major type of solid tumor there is. The drug has a PDUFA date of Feb. 23 for its label expansion into first-line metastatic breast cancer. Barring the introduction of small-molecule competitors from Pfizer (NYSE: PFE  ) or another big pharma, Avastin's growth rate won't be hampered any time soon.  

Except for the fact that it doesn't pay a dividend, Genentech is becoming the new Johnson & Johnson (NYSE: JNJ  ) . It continues to post quarter after quarter of double-digit revenue and earnings growth. It peddles biologics, and since there is not yet a good regulatory pathway in the U.S. giving generic-drug makers a chance to produce biogenerics, discount competitors against its top drugs aren't likely to emerge any time soon.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 538563, ~/Articles/ArticleHandler.aspx, 11/23/2014 9:51:08 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement